Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    CLN-081

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Taiho & Cullinan Zipalertinib Meets Primary Endpoint In NSCLC Trial
    Taiho & Cullinan Zipalertinib Meets Primary Endpoint In NSCLC Trial

    28 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/taiho-pharmaceutical-taiho-oncology-and-cullinan-therapeutics-announce-primary-endpoint-met-in-phase-2b-trial-of-zipalertinib-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-who-have-receiv-302362492.html

    PR NEWSWIRE
    28 Jan 2025
    Share Share
    Cullinan's Zipalertinib Shows Positive Pivotal Phase 2b REZILIENT1 Data
    Cullinan's Zipalertinib Shows Positive Pivotal Phase 2b REZILIENT1 Data

    01 Jun 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/06/01/2891804/0/en/Cullinan-Therapeutics-Announces-Positive-Initial-Data-from-Pivotal-Phase-2b-REZILIENT1-Study-of-Zipalertinib.html

    GLOBENEWSWIRE
    01 Jun 2024
    Share Share
    REZILIENT3 Global First-Line Trial of Zipalertinib Launched for NSCLC
    REZILIENT3 Global First-Line Trial of Zipalertinib Launched for NSCLC

    03 Aug 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/rezilient3-global-first-line-trial-of-zipalertinib-launched-in-patients-with-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-301893051.html

    PR NEWSWIRE
    03 Aug 2023
    Share Share